Elicio Therapeutics Maintains Buy Rating with $12.50 Price Target Consensus

JonesTrading maintains a Buy rating for Elicio Therapeutics, with an analyst consensus of Moderate Buy and a price target consensus of $12.50. The company reported a quarterly GAAP net loss of $11.21 million, compared to $8.95 million last year. Soumit Roy, the analyst covering Elicio Therapeutics, has a 19.52% success rate on recommended stocks and an average return of -23.6%.

Elicio Therapeutics, Inc. (ELTX), a clinical-stage biotechnology company, has reported its second quarter 2025 financial results and provided updates on its cancer immunotherapy pipeline. The company's stock is currently trading under the ticker symbol ELTX.

The Independent Data Monitoring Committee (IDMC) recommended continuing the ELI-002 7P Phase 2 study in pancreatic cancer without modifications, with final disease-free survival (DFS) analysis expected in Q4 2025. Financial highlights for Q2 2025 include a $10 million non-dilutive financing secured in June 2025. Research and development (R&D) expenses were $7.0 million, down from $8.2 million in Q2 2024, and the company reported a net loss of $10.6 million. The cash position of $22.1 million is expected to fund operations into Q1 2026, beyond the anticipated Phase 2 final analysis. Elicio plans to request an End-of-Phase 2 FDA meeting to finalize the regulatory strategy for ELI-002's pivotal Phase 3 trial following the final DFS analysis.

Elicio's lead product, ELI-002, is an AMP-powered therapeutic vaccine targeting mKRAS mutations in pancreatic and colorectal cancers. The company has already aligned with the FDA on key elements of the planned Phase 3 study design and maintains a cash runway extending into Q1 2026. Previous Phase 1 data showed promising results with 16.3-month median recurrence-free survival and 28.9-month median overall survival.

JonesTrading maintains a Buy rating for Elicio Therapeutics, with an analyst consensus of Moderate Buy and a price target consensus of $12.50. The company reported a quarterly GAAP net loss of $11.21 million, compared to $8.95 million last year. Soumit Roy, the analyst covering Elicio Therapeutics, has a 19.52% success rate on recommended stocks and an average return of -23.6%.

References:
[1] https://www.stocktitan.net/news/ELTX/
[2] https://www.stocktitan.net/news/ELTX/